litlas
ログインアカウント作成

C. David Sjöström

1995–2024 年に発表

64
論文数
19,855
被引用数
45
h 指数
64
i10 指数

被引用数

C. David Sjöström の年別被引用数1996 年: 被引用 1 件1997 年: 被引用 3 件1998 年: 被引用 5 件1999 年: 被引用 8 件2000 年: 被引用 14 件2001 年: 被引用 20 件2002 年: 被引用 25 件2003 年: 被引用 32 件2004 年: 被引用 38 件2005 年: 被引用 44 件2006 年: 被引用 18 件2007 年: 被引用 32 件2008 年: 被引用 94 件2009 年: 被引用 118 件2010 年: 被引用 94 件2011 年: 被引用 96 件2012 年: 被引用 114 件2013 年: 被引用 146 件2014 年: 被引用 153 件2015 年: 被引用 143 件2016 年: 被引用 139 件2017 年: 被引用 136 件2018 年: 被引用 130 件2019 年: 被引用 379 件2020 年: 被引用 490 件2021 年: 被引用 795 件2022 年: 被引用 851 件2023 年: 被引用 833 件2024 年: 被引用 1,133 件2025 年: 被引用 556 件2026 年: 被引用 18 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,084 件、この内訳の 21.2%イギリス: 引用元論文 850 件、この内訳の 8.6%中国: 引用元論文 543 件、この内訳の 5.5%イタリア: 引用元論文 481 件、この内訳の 4.9%ドイツ: 引用元論文 453 件、この内訳の 4.6%カナダ: 引用元論文 416 件、この内訳の 4.2%オーストラリア: 引用元論文 403 件、この内訳の 4.1%スウェーデン: 引用元論文 379 件、この内訳の 3.9%オランダ: 引用元論文 366 件、この内訳の 3.7%日本: 引用元論文 330 件、この内訳の 3.4%フランス: 引用元論文 294 件、この内訳の 3%スペイン: 引用元論文 287 件、この内訳の 2.9%
0%21.2%その他 30%

機関

分野

  • Medicine90.2%
  • Biochemistry, Genetics and Molecular Biology4.7%
  • Physics and Astronomy1.6%
  • Neuroscience0.8%
  • Health Professions0.8%
  • Nursing0.4%
  • その他1.5%

トピック

  • Diabetes Treatment and Management14.2%
  • Bariatric Surgery and Outcomes8.7%
  • Chronic Kidney Disease and Diabetes5.9%
  • Pancreatic function and diabetes4.4%
  • Diet and metabolism studies3.8%
  • Metabolism, Diabetes, and Cancer3.3%
  • その他59.7%

共著者

全論文

検索で開く
  1. Dapagliflozin in Patients with Chronic Kidney Disease

    著者: Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter, Glenn M. Chertow, Tom Greene, Fan Fan Hou, Johannes F.E. Mann, John J.V. McMurray, Magnus Lindberg, Peter Rossing, C. David Sjöström, Roberto D. Toto, Anna-Maria Langkilde, David C. Wheeler - New England Journal of Medicine 2020 被引用: 5,197

  2. Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

    著者: Lars Sjöström, Kristina Narbro, C. David Sjöström, Kristjan Karason, Bo Larsson, Hans Wedel, Ted Lystig, Marianne Sullivan, Claude Bouchard, Björn Carlsson, Calle Bengtsson, S Dahlgren, Anders Gummesson, Peter Jacobson, Jan Karlsson, Anna‐Karin Lindroos, Hans Lönroth, Ingmar Näslund, Torsten Olbers, Kaj Stenlöf, Jarl Torgerson, Göran I. Ågren, Lena Carlsson - New England Journal of Medicine 2007 被引用: 4,629

  3. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

    著者: David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, Robert D. Toto, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink - The Lancet Diabetes & Endocrinology 2020 被引用: 530

  4. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

    著者: David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Roberto Pecoits‐Filho, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Kausik Umanath, Anna Maria Langkilde, Hiddo J.L. Heerspink - Kidney International 2021 被引用: 397

  5. Bariatric Surgery and Long-term Cardiovascular Events

    著者: Lars Sjöström, Markku Peltonen, Peter Jacobson, C. David Sjöström, Kristjan Karason, Hans Wedel, Sofie Ahlin, Åsa Anveden, Calle Bengtsson, Gerd Bergmark, Claude Bouchard, Björn Carlsson, S Dahlgren, Jan Karlsson, Anna‐Karin Lindroos, Hans Lönroth, Kristina Narbro, Ingmar Näslund, Torsten Olbers, Per‐Arne Svensson, Lena Carlsson - JAMA 2012 被引用: 1,623

  6. Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region

    著者: Patrik Sibolt, Lina Andersson, L. Calmels, C. David Sjöström, Ulf Bjelkengren, Poul Geertsen, C.F. Behrens - Physics and Imaging in Radiation Oncology 2020 被引用: 248

  7. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

    著者: Niels Jongs, Tom Greene, Glenn M. Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink - The Lancet Diabetes & Endocrinology 2021 被引用: 208

  8. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

    著者: Glenn M. Chertow, Priya Vart, Niels Jongs, Robert D. Toto, Jose Luis Gorriz, Fan Fan Hou, John J.V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink - Journal of the American Society of Nephrology 2021 被引用: 196

  9. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

    著者: Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Tom Greene - The Lancet Diabetes & Endocrinology 2021 被引用: 194

  10. Once-Weekly Exenatide in Youth With Type 2 Diabetes

    著者: William V. Tamborlane, Raafat Bishai, David H. Geller, Naim Shehadeh, Dalia Al‐Abdulrazzaq, Evelina Mánica Vazquez, Eva Karoly, Tünde Troja, Orlando Doehring, Debra Carter, John T. Monyak, C. David Sjöström - Diabetes Care 2022 被引用: 89

  11. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    著者: David C. Wheeler, Bergur V. Stefánsson, М. М. Батюшин, Oleksandr Bilchenko, David Z.I. Cherney, Glenn M. Chertow, Walter Douthat, Jamie P. Dwyer, Elizabeth Escudero, Roberto Pecoits‐Filho, Hans Furuland, José Luis Górriz, Tom Greene, Hermann Haller, Fan Fan Hou, Shin‐Wook Kang, Rey Isidto, Dinesh Khullar, Patrick B. Mark, John J.V. McMurray, Naoki Kashihara, Michał Nowicki, Frederik Persson, Ricardo Correa‐Rotter, Peter Rossing, Robert D. Toto, Kausik Umanath, Pham Van Bui, István Wittmann, Magnus Lindberg, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink - Nephrology Dialysis Transplantation 2020 被引用: 190

  12. Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD

    著者: Niels Jongs, Glenn M. Chertow, Tom Greene, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Naoki Kashihara, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink - Journal of the American Society of Nephrology 2022 被引用: 86

  13. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial

    著者: Lars Sjöström, Anders Gummesson, C. David Sjöström, Kristina Narbro, Markku Peltonen, Hans Wedel, Calle Bengtsson, Claude Bouchard, Björn Carlsson, S Dahlgren, Peter Jacobson, Kristjan Karason, Jan Karlsson, Bo Larsson, Anna‐Karin Lindroos, Hans Lönroth, Ingmar Näslund, Torsten Olbers, Kaj Stenlöf, Jarl Torgerson, Lena Carlsson - The Lancet Oncology 2009 被引用: 759

  14. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

    著者: Glenn M. Chertow, Priya Vart, Niels Jongs, Robert D. Toto, José Luis Górriz, Fan Fan Hou, McMurray, JJV, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Anna Maria Langkilde, David C. Wheeler, Heerspink, HJL, DAPA-CKD Trial Committees and Investigators, . - 2021 被引用: 101

  15. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

    著者: Lindsay E. Clegg, Robert C. Penland, Srinivas Bachina, David W. Boulton, Marcus Thuresson, Hiddo J.L. Heerspink, Stephanie M. Gustavson, C. David Sjöström, James A. Ruggles, Adrian F. Hernandez, John B. Buse, Robert J. Mentz, Rury R. Holman - Cardiovascular Diabetology 2019 被引用: 94

  16. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial

    著者: Serge Jabbour, Juan P. Frías, Azazuddin Ahmed, Elise Hardy, Jasmine Choi, C. David Sjöström, Cristian Guja - Diabetes Care 2020 被引用: 68

  17. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

    著者: Carol A. Pollock, Bergur V. Stefánsson, Daniel Reyner, Peter Rossing, C. David Sjöström, David C. Wheeler, Anna Maria Langkilde, Hiddo J.L. Heerspink - The Lancet Diabetes & Endocrinology 2019 被引用: 200

  18. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

    著者: John J.V. McMurray, David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa‐Rotter, Glenn M. Chertow, Tom Greene, Claes Held, Fan Fan Hou, Johannes F.E. Mann, Peter Rossing, C. David Sjöström, Roberto D. Toto, Anna Maria Langkilde, Hiddo J.L. Heerspink - Circulation 2020 被引用: 141

  19. Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study

    著者: Annemarie B. van der Aart‐van der Beek, Ellen M. Apperloo, Niels Jongs, Dennis B. Rouw, C. David Sjöström, Iris Friedli, L. E. B. Johansson, Daniël H. van Raalte, Klaas Hoogenberg, Hiddo J.L. Heerspink - Diabetes Obesity and Metabolism 2023 被引用: 29

  20. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

    著者: Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs, Glenn M. Chertow, Mikhail Kosiborod, Fan Fan Hou, John J.V. McMurray, Peter Rossing, Ricardo Correa‐Rotter, Raisa Kurlyandskaya, Bergur V. Stefánsson, Robert D. Toto, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink, David C. Wheeler, Glenn M. Chertow, Ricardo Correa‐Rotter, Tom Greene, Fan Fan Hou, John J.V. McMurray, Peter Rossing, Robert D. Toto, Bergur V. Stefánsson, Anna Maria Langkilde, Laura Maffei, Pablo Raffaele, S. Solís, César A. Arias, Dov Aizenberg, Carolina Lúquez, Cesar Javier Zaidman, Natalia Cluigt, M. Mayer, A Alvarisqueta, A. Wassermann, Rafaël Maldonado, J. Bittar, M. Maurich, L.E. Gaite, Nicole Garcia, Leonardo Sivak, Pablo Ramallo, Juan Carlos Santos, Ruben Garcia Duran, Juan Oddino, A Marañón, Lília Nigro Maia, Dánae Duana Ávila, Elvino Barros, Maria H Vidotti, Daniel Panarotto, Irene de Lourdes Noronha, Luiz Alberto Andreotti Turatti, Luciane Mônica Deboni, María Eugênia Fernandes Canziani, Miguel C. Riella, Marcelo Rodrigues Bacci, Raphael Paschoalin, R. J. Franco, João Carlos Goldani, Eric St-Amour, Ann Steele, Ronald Goldenberg, S.B. Pandeya, Harpreet S. Bajaj, David Z.I. Cherney, Stéphanie Kaiser, James Conway, Sharron Chow, G.S. Bailey, Jean‐Philippe Lafrance, Jonathan Winterstein, Serge Cournoyer, Daniel Gaudet, F. Madore, Robyn L. Houlden, Ashley Dowell, Michel R. Langlois, Nicola Muirhead, Hasnain Khandwala, Anna S. Levin, Fan Fan Hou, Ying Xue, Zuo Li, Chuan‐Ming Hao, Zhaohui Ni, C Xing, N Chen, Yugang Dong, Rong Zhou, Xiao Xu, Yiping Zou, Chu Wang, Liu B, Qian Chen, Miao Lin, Qin Luo, David Zhang, Jing Wang ほか 339 名 - European Heart Journal 2021 被引用: 122

  21. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial

    著者: David C. Wheeler, Niels Jongs, Bergur V. Stefánsson, Glenn M. Chertow, Tom Greene, Fan Fan Hou, Anna Maria Langkilde, John J.V. McMurray, Peter Rossing, Michał Nowicki, István Wittmann, Ricardo Correa‐Rotter, C. David Sjöström, Robert D. Toto, Hiddo J.L. Heerspink - Nephrology Dialysis Transplantation 2021 被引用: 94

  22. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study

    著者: Paola Fioretto, Stefano Del Prato, John B. Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C. David Sjöström, Peter Sartipy, On Behalf of the DERIVE Study Investigators - Diabetes Obesity and Metabolism 2018 被引用: 191

  23. Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: Initial experience and dosimetric benefits

    著者: Lina M. Åström, C.F. Behrens, L. Calmels, C. David Sjöström, Poul Geertsen, Lene Sonne Mouritsen, Eva Serup‐Hansen, Henriette Lindberg, Patrik Sibolt - Radiotherapy and Oncology 2022 被引用: 111

  24. Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

    著者: John J.V. McMurray, David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa‐Rotter, Glenn M. Chertow, Fan Fan Hou, Peter Rossing, C. David Sjöström, Scott D. Solomon, Robert D. Toto, Anna Maria Langkilde, Hiddo J.L. Heerspink - JACC Heart Failure 2021 被引用: 106